Single molecule analysis of C-Myb alternative splicing reveals novel classifiers for precursor B-ALL

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Zhou, Ye E ^a   O'Rourke, John P ^a   Edwards, Jeremy S ^a   Ness, Scott A ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; PROTEIN C MYB; MESSENGER RNA; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALTERNATIVE RNA SPLICING; ARTICLE; C MYB GENE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EXON; GENE; GENE EXPRESSION; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; CHILD; CLASSIFICATION; GENETICS; METABOLISM; METHODOLOGY; SURVIVAL; TUMOR CELL LINE;

ALTERNATIVE SPLICING; CELL LINE, TUMOR; CHILD; EXONS; HUMANS; POLYMERASE CHAIN REACTION; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-MYB; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80051625937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022880     Document Type: Article

References (36)

1. Mucenski ML, McLain K, Kier AB, Swerdlow SH, Schreiner CM, et al. (1991) A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell 65: 677-689.
2. Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, et al. (2005) c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell 8: 153-166.
3. Sakamoto H, Dai G, Tsujino K, Hashimoto K, Huang X, et al. (2006) Proper levels of c-Myb are discretely defined at distinct steps of hematopoietic cell development. Blood 108: 896-903.
4. Fahl SP, Crittenden RB, Allman D, Bender TP, (2009) c-Myb is required for pro-B cell differentiation. J Immunol 183: 5582-5592.
5. Hu T, Simmons A, Yuan J, Bender TP, Alberola-Ila J, (2010) The transcription factor c-Myb primes CD4+CD8+ immature thymocytes for selection into the iNKT lineage. Nat Immunol 11: 435-441.
6. Gonda TJ, Buckmaster C, Ramsay RG, (1989) Activation of c-myb by carboxy-terminal truncation: relationship to transformation of murine haemopoietic cells in vitro. EMBO J 8: 1777-1783.
7. Dash AB, Orrico FC, Ness SA, (1996) The EVES motif mediates both intermolecular and intramolecular regulation of c-Myb. Genes Dev 10: 1858-1869.
8. Lei W, Rushton JJ, Davis LM, Liu F, Ness SA, (2004) Positive and negative determinants of target gene specificity in myb transcription factors. J Biol Chem 279: 29519-29527.
9. Ramsay RG, Gonda TJ, (2008) MYB function in normal and cancer cells. Nat Rev Cancer 8: 523-534.
10. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, et al. (2007) Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet 39: 593-595.
11. Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, et al. (2007) The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood 110: 1251-1261.
12. Persson M, Andren Y, Mark J, Horlings HM, Persson F, et al. (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A 106: 18740-18744.
13. Zhou Y, Ness SA, (2011) Myb proteins: angels and demons in normal and transformed cells. Front Biosci 16: 1109-1131.
14. Ness SA, Marknell A, Graf T, (1989) The v-myb oncogene product binds to and activates the promyelocyte-specific mim-1 gene. Cell 59: 1115-1125.
15. Introna M, Golay J, Frampton J, Nakano T, Ness SA, et al. (1990) Mutations in v-myb alter the differentiation of myelomonocytic cells transformed by the oncogene. Cell 63: 1289-1297.
16. Liu F, Lei W, O'Rourke JP, Ness SA, (2006) Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb. Oncogene 25: 795-805.
17. Quintana AM, Zhou YE, Pena JJ, O'Rourke JP, Ness SA, (2011) Dramatic repositioning of c-Myb to different promoters during the cell cycle observed by combining cell sorting with chromatin immunoprecipitation. PLoS One 6: e17362.
18. O'Rourke JP, Ness SA, (2008) Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities. Mol Cell Biol 28: 2091-2101.
19. Shen-Ong GL, (1987) Alternative internal splicing in c-myb RNAs occurs commonly in normal and tumor cells. EMBO J 6: 4035-4039.
20. Westin EH, Gorse KM, Clarke MF, (1990) Alternative splicing of the human c-myb gene. Oncogene 5: 1117-1124.
21. Schuur ER, Rabinovich JM, Baluda MA, (1994) Distribution of alternatively spliced chicken c-myb exon 9A among hematopoietic tissues. Oncogene 9: 3363-3365.
22. Woo CH, Sopchak L, Lipsick JS, (1998) Overexpression of an alternatively spliced form of c-Myb results in increases in transactivation and transforms avian myelomonoblasts. J Virol 72: 6813-6821.
23. Ramsay RG, Ishii S, Nishina Y, Soe G, Gonda TJ, (1989) Characterization of alternate and truncated forms of murine c-myb proteins. Oncogene Res 4: 259-269.
24. Kumar A, Baker SJ, Lee CM, Reddy EP, (2003) Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb. Mol Cell Biol 23: 6631-6645.
25. Zhu J, Shendure J, Mitra RD, Church GM, (2003) Single molecule profiling of alternative pre-mRNA splicing. Science 301: 836-838.
26. Rushton JJ, Davis LM, Lei W, Mo X, Leutz A, et al. (2003) Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins. Oncogene 22: 308-313.
27. Mullighan CG, (2011) New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Clin Cancer Res 17: 396-400.
28. Hu YL, Ramsay RG, Kanei-Ishii C, Ishii S, Gonda TJ, (1991) Transformation by carboxyl-deleted Myb reflects increased transactivating capacity and disruption of a negative regulatory domain. Oncogene 6: 1549-1553.
29. Bies J, Wolff L, (1997) Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway. Oncogene 14: 203-212.
30. Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, et al. (2010) Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 115: 1394-1405.
31. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, et al. (2007) The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14: 185-193.
32. Sun S, Zhang Z, Sinha R, Karni R, Krainer AR, (2010) SF2/ASF autoregulation involves multiple layers of post-transcriptional and translational control. Nat Struct Mol Biol 17: 306-312.
33. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, et al. (2010) Regulation of alternative splicing by histone modifications. Science 327: 996-1000.
34. Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, et al. (2010) c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest 120: 593-606.
35. Somervaille TC, Cleary ML, (2010) Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells? Int J Hematol 91: 735-741.
36. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.